1.5100
10-January-25 15:45:00
15 minutes delayed
Stocks
+0.0600
+4.14%
Today's range
1.4100 - 1.5300
ISIN
N/A
Source
NASDAQ
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
08 Feb 2021 07:00:01 By Nasdaq GlobeNewswire